Regeneron Pharmaceuticals, Inc. (REGN) retreated -3.43% to reach at the floor price of $371.32 as the company is set to share its latest quarterly earnings prior to opening bell on May 05, 2016. REGN stock trades between $370.77 and $381.73 before the earnings release. Let’s take a closer look at the March 2016 earnings estimates, particularly the things investors should pay close attention to. Earnings (EPS) for the recently concluded quarter is projected to come in at $2.58/share with 1.18B in revenue.
Earnings Track Record: If history is anything to go by, Regeneron Pharmaceuticals, Inc. (REGN) managed to beat quarterly EPS forecasts in 7 of the trailing three fiscal years , and has a positive trend with an average surprise of 58%%. Last time the company reported, Regeneron Pharmaceuticals, Inc. generated $2.83 in earnings per share, missing the mean forecast of $3.36. Revenues reached $1.1B in the December 2015 quarter, which was higher than the consensus $1.17B projection. On the other hand, in the September 2015 quarter it recorded a net $1.14B revenue with EPS of $3.47. Wall Street had projected $1.05B and $3.2, respectively. For comparison, there was a revenue of $998.62M and earnings of $2.89 in the June 2015 quarter.
Future Earnings: After upcoming financial results, all eyes will be on the outlook or guidance for the next reporting quarter (June 2016). Analysts, on average, predict Regeneron Pharmaceuticals, Inc. to earn $2.73 in earnings per share (EPS) on revenue of $1.24B. The earnings-per-share consensus range is $1.97-$3.47 on sales between $1.16B and $1.36B.
Stock Trend vs. Analyst View: The stock is trading up 6.41 percent versus 1-year low of $348.96 and stands -38.72 lower from its peak of $605.93. The consensus price target of $480 means that the market expects Company shares to increase by 29.27% in the short run. The sell-side target prices range from $325 to $668. In the last month the stock has moved in price -8.38 , with a one year change of -21.69%. The last trading session volume compares with the 958.18K average and market worth floats around $40.53B.
Recent Analyst Rating Changes: The buoyancy in the prospect of Regeneron Pharmaceuticals, Inc. (REGN) is getting weaker by the somewhat negative sentiment (2.30on a 5-point scale) that brokerage firms have issued concerning it. Wall Street analysts on the average recommend the company shares as Overweight. Wells Fargo has been covering shares of , so it’s most recent view is worth a look. In a research note released on April 20, 2016, analysts at Wells Fargo downgraded the stock from *Market Perform* to Outperform. Another noteworthy analyst activity was recorded on March 16, 2016. Chardan Capital Markets analytsts lowered their recommendation for REGN to Neutral from *Sell*.